Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Antibodies, Monoclonal/adverse effects"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jeroen M. K. de Filette, Stéphanie André, Lynn De Mey, Sandrine Aspeslagh, Rafik Karmali, Bart J Van der Auwera, Bert Bravenboer
Publikováno v:
BMC Endocrine Disorders. 22
Background Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 and its ligand (PD-1/PD-L1) have become the current standard-of-care for advanced cancers. This novel therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223f73b55f7074a181cd6cbfe318b703
https://doi.org/10.1186/s12902-022-01190-5
https://doi.org/10.1186/s12902-022-01190-5
Autor:
Leonel, Renan Martinelli, Reis, Flávia Medeiros Dutra, Andolfatto, Daniel, Oliveira, Gabriela Gonçalves de
Publikováno v:
Revista Brasileira de Cancerologia; Vol. 68 No. 3 (2022): July/Aug./Sept.; e-152316
Revista Brasileira de Cancerologia; Vol. 68 Núm. 3 (2022): jul./ago./sept; e-152316
Revista Brasileira de Cancerologia; v. 68 n. 3 (2022): jul./ago./set.; e-152316
Revista Brasileira de Cancerologia
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
Revista Brasileira de Cancerologia; Vol. 68 Núm. 3 (2022): jul./ago./sept; e-152316
Revista Brasileira de Cancerologia; v. 68 n. 3 (2022): jul./ago./set.; e-152316
Revista Brasileira de Cancerologia
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
Introduction: The use of monoclonal antibodies has been incorporated into cancer treatment protocols, once their effectiveness has been proven. This type of therapy is costly and its acquisition is still an obstacle for the patient. Objective: To des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3056::e603f45d5cf30beed093856f3be625e1
https://rbc.inca.gov.br/index.php/revista/article/view/2316
https://rbc.inca.gov.br/index.php/revista/article/view/2316
Autor:
Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, F Stephen Hodi, Alvaro Taus, Maria Martinez Garcia, Valentina Boni, Joseph P Eder, Navid Hafez, Ryan Sullivan, David Mcdermott, Stephane Champiat, Sandrine Aspeslagh, Catherine Terret, Anna-Maria Jegg, Wolfgang Jacob, Michael A Cannarile, Carola Ries, Konstanty Korski, Francesca Michielin, Randolph Christen, Galina Babitzki, Carl Watson, Georgina Meneses-Lorente, Martin Weisser, Dominik Rüttinger, Jean-Pierre Delord, Aurelien Marabelle
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol. 10, no.5, p. e004076 (2022)
BackgroundThis phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2c2dc4accf632390ea464a967fc522a
https://pubmed.ncbi.nlm.nih.gov/35577503
https://pubmed.ncbi.nlm.nih.gov/35577503
Autor:
Wolfgang Willenbacher, Brian Fox, Peter de Nully Brown, Judit Jørgensen, Neus Domper Rubio, Marie-Laure Casadebaig, Richard Greil, Hele Everaus, Ulrich Jäger, Lorenz Trümper, David Cunningham, Oliver Manzke, Thomas Stauffer Larsen, Krish Patel, Justine Dell’Aringa, Nurgul Kilavuz, Grzegorz S. Nowakowski, Nagesh Kalakonda, Robert Manges, Javier Munoz
Publikováno v:
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell’Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell'Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M-L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell'Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M-L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can incre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d8c12cf157023fa610230261b321fc
https://portal.findresearcher.sdu.dk/da/publications/a1eda3b7-edc6-42d6-9940-c2ac96b43009
https://portal.findresearcher.sdu.dk/da/publications/a1eda3b7-edc6-42d6-9940-c2ac96b43009
Autor:
Claus Kristensen, Line Brøndum, Jan F. Evensen, Jens Overgaard, C. Maare, Jan Alsner, Jørgen Johansen, Brita Singers Sørensen, Jesper Grau Eriksen, Lisbeth Juhler Andersen, Hanne Primdahl
Publikováno v:
Brøndum, L, Alsner, J, Sørensen, B S, Maare, C, Johansen, J, Primdahl, H, Evensen, J F, Kristensen, C A, Andersen, L J, Overgaard, J & Eriksen, J G 2018, ' Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial ', Acta Oncologica, vol. 57, no. 9, pp. 1159-1164 . https://doi.org/10.1080/0284186X.2018.1464664
Brøndum, L, Alsner, J, Sørensen, B S, Maare, C, Johansen, J, Primdahl, H, Evensen, J F, Kristensen, C A, Andersen, L J, Overgaard, J & Eriksen, J G 2018, ' Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab : results from the DAHANCA 19 trial ', Acta Oncologica, vol. 57, no. 9, pp. 1159-1164 . https://doi.org/10.1080/0284186X.2018.1464664
Brøndum, L, Alsner, J, Sørensen, B S, Maare, C, Johansen, J, Primdahl, H, Evensen, J F, Kristensen, C A, Andersen, L J, Overgaard, J & Eriksen, J G 2018, ' Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab : results from the DAHANCA 19 trial ', Acta Oncologica, vol. 57, no. 9, pp. 1159-1164 . https://doi.org/10.1080/0284186X.2018.1464664
Purpose: To study the associations between development of moderate to severe skin rash, clinical outcome, and single nucleotide polymorphisms (SNPs) in candidate genes in head and neck cancer patients from the DAHANCA 19 trial receiving the EGFR-inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba1e936eb750b6dde160b2d983dbcb95
Autor:
Alex F. Herrera, Bo Huang, Camilla Fowst, David J. Lewis, Fiona Miall, Pier Luigi Zinzani, John Radford, Graham P. Collins, Armando Santoro, Satjit Brar, William Townsend, Aron Thall, C. Burton
Publikováno v:
Blood Adv
Herrera, A F, Burton, C, Radford, J, Miall, F, Townsend, W, Santoro, A, Zinzani, P L, Lewis, D, Fowst, C, Brar, S, Huang, B, Thall, A & Collins, G P 2021, ' Avelumab in relapsed/refractory classical Hodgkin lymphoma : phase 1b results from the JAVELIN Hodgkins trial ', Blood Advances, vol. 5, no. 17, pp. 3387-3396 . https://doi.org/10.1182/BLOODADVANCES.2021004511
Herrera, A F, Burton, C, Radford, J, Miall, F, Townsend, W, Santoro, A, Zinzani, P L, Lewis, D, Fowst, C, Brar, S, Huang, B, Thall, A & Collins, G P 2021, ' Avelumab in relapsed/refractory classical Hodgkin lymphoma : phase 1b results from the JAVELIN Hodgkins trial ', Blood Advances, vol. 5, no. 17, pp. 3387-3396 . https://doi.org/10.1182/BLOODADVANCES.2021004511
The 9p24.1 chromosomal alteration in classical Hodgkin lymphoma (cHL) is associated with increased expression of programmed death ligand 1 (PD-L1)/PD-L2 and an immunosuppressive tumor microenvironment. Blockade of PD-L1/PD-1 interactions with aveluma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::592fc4d3b23864aef2a200dd739b1a36
https://pubmed.ncbi.nlm.nih.gov/34477818
https://pubmed.ncbi.nlm.nih.gov/34477818
Autor:
Delphine Sterlin, Guy Gorochov
Publikováno v:
Pharmacology
Pharmacology, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩
Pharmacology, Karger, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩
Pharmacology, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩
Pharmacology, Karger, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩
Background: Extensive efforts have been made in optimizing monoclonal immunoglobulin (Ig)G antibodies for use in clinical practice. Accumulating evidence suggests that IgA or anti-FcαRI could also represent an exciting avenue toward novel therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc9a12b1182e8d150ab11b2aa001c856
https://hal.sorbonne-universite.fr/hal-03139698
https://hal.sorbonne-universite.fr/hal-03139698
Publikováno v:
Journal of Travel Medicine, Vol. 28, No 3 (2021) P. taaa235
We consider the safety of live vaccines when used in patients on natalizumab, a long-acting immunosuppressive monoclonal antibody. Based on this drug's specific mode of action we propose a benefit/risk assessment on a case-by-case basis with individu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::877070b2c123de0203afb40aba6bd5d8
https://pubmed.ncbi.nlm.nih.gov/33367888
https://pubmed.ncbi.nlm.nih.gov/33367888
Autor:
Alexander A. Navarini, Curdin Conrad, Alessio Mylonas, Anne-Karine Lapointe, Jeremy Di Domizio, Olivier Demaria, Michel Gilliet, Cyrine Belkhodja, Lars E. French, Maxime Vernez
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Nature Communications
Nature communications, vol. 9, no. 1, pp. 25
Nature Communications
Nature communications, vol. 9, no. 1, pp. 25
Although anti-tumor necrosis factor (TNF) agents are highly effective in the treatment of psoriasis, 2–5% of treated patients develop psoriasis-like skin lesions called paradoxical psoriasis. The pathogenesis of this side effect and its distinction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbbc7decb248c10970a313c075620f0f
https://doaj.org/article/180fc992d72e4fcbbf1d606055e86015
https://doaj.org/article/180fc992d72e4fcbbf1d606055e86015